How to Prep for Your First Menopause Visit

What Menopause Actually Is (and Why the Definition Matters for Your Visit)

Menopause is defined as 12 consecutive months without a menstrual period, not caused by pregnancy, breastfeeding, or a medical condition. That clinical definition comes directly from The Menopause Society (formerly NAMS) and shapes how your provider will date your menopause and calculate your "timing window" for hormone therapy. Getting that date right matters because the 2022 Menopause Society Position Statement explicitly ties HRT cardiovascular safety data to time since menopause onset.

The Three Stages Your Provider Will Ask About

Perimenopause begins when ovarian hormone output becomes irregular, typically 4 to 8 years before the final period. Cycles may lengthen, shorten, or skip. Vasomotor symptoms (hot flashes, night sweats) often start here, sometimes years before periods stop.

Menopause is that 12-month marker. Ovarian estrogen and progesterone production fall sharply. FSH rises above 30 IU/L in most women.

Postmenopause covers every year after that marker. Bone loss accelerates most rapidly in the first 3 to 5 years postmenopause, with studies showing trabecular bone sites losing 3 to 5 percent per year without intervention [1].

Why Staging Changes Your Treatment Options

A provider who does not know your stage cannot correctly interpret your FSH result, time your HRT initiation, or assess your cardiovascular risk profile. Write down your last menstrual period date before the visit, even if it was years ago.

Building Your Symptom Log Before the Appointment

Arrive with at least 60 days of written symptom data. A single-page log beats a verbal summary every time because providers can quickly identify patterns, severity trends, and the impact on sleep and daily function.

What to Track Each Day

Record the following daily entries in a notebook or app:

• Hot flash frequency and severity (number of episodes, scale of 1 to 10, time of day)
• Night sweats (did they wake you, did you need to change clothing or bedding)
• Sleep quality (hours, number of awakenings, subjective restfulness)
• Mood and cognition (irritability, anxiety, brain fog episodes)
• Genitourinary symptoms (vaginal dryness, discomfort with intercourse, urinary urgency)
• Musculoskeletal (joint aches, which joints, duration)
• Menstrual pattern (if still cycling: cycle length, flow heaviness, spotting)

The Menopause Rating Scale (MRS) and the Greene Climacteric Scale are validated instruments your provider may use to score severity at your visit [2]. Completing one online before you arrive gives you a baseline score to track against treatment response.

Severity Benchmarks That Matter Clinically

Moderate-to-severe vasomotor symptoms, defined as those that disrupt sleep or daily activity, are the primary indication for systemic hormone therapy per Menopause Society guidance [3]. If you rate 5 or above on a 1-to-10 scale or experience more than 7 hot flashes per day, say so explicitly. That threshold often determines whether a provider moves directly to systemic HRT versus trying low-dose vaginal estrogen first.

Medical History Your Provider Needs on Day One

Your provider will screen you for absolute and relative contraindications to hormone therapy. The screening is not bureaucratic. Certain conditions change the risk-benefit ratio of systemic estrogen enough to require a different treatment pathway entirely.

Absolute Contraindications to Systemic HRT

Bring documentation of any personal history of:

• Estrogen-receptor-positive breast cancer
• Active or recent deep vein thrombosis or pulmonary embolism
• Active or recent arterial thromboembolic event (stroke, MI)
• Undiagnosed abnormal uterine bleeding
• Known or suspected pregnancy
• Severe active liver disease

The FDA label for conjugated equine estrogen (Premarin) and estradiol products lists these contraindications explicitly [4]. Your provider cannot prescribe without screening for them.

Family History Details That Affect Risk Stratification

First-degree relative with breast cancer, ovarian cancer, or a clotting disorder (factor V Leiden, prothrombin gene mutation) all change the conversation. Write down the relative, the condition, and the age at diagnosis. A first-degree relative diagnosed with breast cancer after age 60 carries a different risk implication than one diagnosed at 42.

Current Medications and Supplements

Bring the actual bottles or a typed list that includes dose and frequency. Several drug interactions are clinically significant:

• Thyroid hormone (levothyroxine): Oral estrogen increases thyroid-binding globulin, often requiring a dose adjustment [5].
• Anticoagulants: Transdermal estrogen is preferred over oral when a clotting history exists, but warfarin interactions still require monitoring.
• Antidepressants: SSRIs and SNRIs reduce hot flash frequency by 50 to 60 percent in some trials and may be co-prescribed or used as alternatives [6].

Labs Your Provider Will Likely Order

Most menopause specialists order a standard panel at the first visit. Knowing what to expect reduces appointment anxiety and lets you fast beforehand if needed.

The Core Panel

| Test | Why It Is Ordered | Normal Range at Menopause | |------|-------------------|--------------------------| | FSH | Confirms menopause; typically >30 IU/L postmenopause | >30 IU/L | | Estradiol (E2) | Baseline before HRT; typically <30 pg/mL postmenopause | <30 pg/mL | | TSH | Thyroid dysfunction mimics menopause symptoms | 0.4 to 4.0 mIU/L | | CBC | Rules out anemia as cause of fatigue | Varies | | Comprehensive metabolic panel | Liver function required before HRT; glucose for metabolic risk | Varies | | Fasting lipid panel | Cardiovascular risk baseline | LDL <100 mg/dL optimal | | Vitamin D (25-OH) | Deficiency is common; bone health relevance | 30 to 100 ng/mL |

When Bone Density Testing Applies

The U.S. Preventive Services Task Force recommends bone density screening (DXA) for all women aged 65 and older, and for postmenopausal women younger than 65 who have at least one risk factor for osteoporosis [7]. If you are postmenopausal and have a fracture history, low body weight (BMI <20), or a first-degree relative with a hip fracture, ask your provider whether DXA is appropriate now rather than waiting.

Hormone Panels: What Not to Expect

Saliva or urine hormone panels marketed by compounding pharmacies lack standardization. The Endocrine Society's clinical practice guideline on menopausal hormone therapy does not endorse salivary estradiol for clinical decision-making, citing variable and often inaccurate results [8]. Serum estradiol via immunoassay or LC-MS/MS is the validated standard.

Understanding Hormone Therapy Options Before You Arrive

Walking in with a basic understanding of HRT options lets you have a real conversation rather than spending 20 minutes on introductory definitions.

Systemic Estrogen: Forms and Delivery Routes

Estrogen is available as oral tablets, transdermal patches, gels, sprays, and vaginal rings with systemic absorption. The delivery route matters clinically:

Oral estrogen undergoes hepatic first-pass metabolism, raising SHBG and C-reactive protein, and is associated with a small increase in venous thromboembolism risk compared to transdermal forms [9].

Transdermal estradiol (patches, gels, sprays) bypasses hepatic first-pass metabolism. A large pharmacoepidemiological study published in the BMJ (N=80,396) found transdermal estradiol was not associated with increased VTE risk, while oral estradiol was (odds ratio 1.58, 95% CI 1.10 to 2.27) [9].

Progestogen: Who Needs It and Which Type

Any woman with an intact uterus requires a progestogen alongside systemic estrogen to protect against endometrial hyperplasia and cancer. Options include:

• Oral micronized progesterone (Prometrium): Body-identical; favorable sleep and mood profile in some patients; preferred in most current guidelines.
• Medroxyprogesterone acetate (MPA): Used in the WHI trials; associated in the combined-arm analysis with a small increase in breast cancer risk after 5.6 years, a finding that does not appear with micronized progesterone in observational data [10].
• Levonorgestrel IUD (Mirena): Provides local endometrial protection while allowing systemic estrogen without significant systemic progestogen exposure.

Women without a uterus take estrogen alone. The WHI estrogen-alone trial (N=10,739, average follow-up 7.1 years) found estrogen alone did not increase breast cancer risk and was associated with a reduced breast cancer hazard ratio of 0.77 (95% CI 0.62 to 0.95) [10].

Non-Hormonal Options to Discuss

If HRT is contraindicated or declined, several evidence-based alternatives exist:

• Fezolinetant (Veozah): FDA-approved May 2023 as the first non-hormonal neurokinin B receptor antagonist for moderate-to-severe vasomotor symptoms. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg reduced mean daily hot flash frequency by 63 percent at week 12 versus 45 percent with placebo [11].
• Paroxetine 7.5 mg (Brisdelle): The only FDA-approved SSRI for hot flashes; modest effect size but appropriate when HRT is contraindicated.
• Venlafaxine 37.5 to 75 mg: Off-label but commonly used; reduces hot flash frequency by approximately 50 percent in randomized data [6].
• Ospemifene (Osphena): FDA-approved selective estrogen receptor modulator for dyspareunia due to genitourinary syndrome of menopause (GSM), taken orally.

The "Timing Hypothesis" and Why Your Age at Menopause Matters

The cardiovascular benefit or risk from HRT depends heavily on when it is started relative to menopause. This is called the "timing hypothesis" or "window of opportunity."

The 2022 Menopause Society Position Statement states: "For women who are aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture" [3].

The WHI re-analysis by Manson et al. In JAMA (2017) found that women who initiated HRT within 10 years of menopause had a coronary heart disease hazard ratio of 0.70 (95% CI 0.52 to 0.95), while women starting 20 or more years after menopause had a hazard ratio of 1.28 (95% CI 1.03 to 1.58) [12]. Same hormone. Opposite cardiovascular direction. Timing is the variable.

If you are 58 years old and just two years postmenopause, your timing window is still open. If you are 72 and 22 years postmenopause, the risk calculus is genuinely different.

Questions to Ask Your Provider at the First Visit

Bring this list in writing. A provider seeing 20 patients a day will cover more ground when you direct the conversation.

On diagnosis and staging:

1. "Based on my FSH and symptom history, am I perimenopausal or postmenopausal?"
2. "Do I need any additional testing before you can recommend a treatment?"

On hormone therapy eligibility: 3. "Given my personal and family history, am I a candidate for systemic HRT?" 4. "If yes, would you recommend oral or transdermal estrogen, and why?" 5. "Do I need a progestogen, and if so, would you prescribe micronized progesterone rather than MPA?"

On non-hormonal options: 6. "If I prefer to avoid hormones, what is the most effective non-hormonal option for my specific symptoms?" 7. "Is fezolinetant appropriate for me, or does my profile fit an SSRI/SNRI better?"

On long-term health: 8. "At my age and time since menopause, what does the bone density data say I should do?" 9. "Should I have a DXA scan now or wait until 65?" 10. "How often will you recheck my labs once treatment is started?"

On monitoring and follow-up: 11. "What symptom improvement should I expect in the first 4 to 8 weeks, and what would prompt you to adjust the dose?" 12. "At what point would you consider stopping hormone therapy, and how would we taper it?"

What to Expect During and After the Visit

The first menopause visit typically runs 30 to 60 minutes in a dedicated menopause clinic. A primary care appointment may be shorter. Expect:

• A detailed symptom review using your log
• A physical exam (blood pressure, weight, pelvic exam in many practices)
• Lab orders to be collected same-day or at a nearby facility
• A treatment discussion, which may be deferred until lab results return

Most providers schedule a follow-up 4 to 8 weeks after starting any new hormone regimen to assess symptom response and check estradiol levels (target: 40 to 100 pg/mL for most women on systemic therapy).

If You Are Using HealthRX Telehealth

A HealthRX intake includes a structured symptom questionnaire, medication reconciliation, and a synchronous video visit with a licensed clinician. Lab orders are sent electronically to a national network of draw sites. Prescriptions, when clinically appropriate, are sent to your preferred pharmacy or compounded per our formulary within 24 to 48 hours of lab result review.

Bone Health: The Long-Term Conversation to Start Early

Menopause-associated bone loss is not a distant concern. Trabecular bone (spine, hip) begins accelerating immediately after the final menstrual period. The NOF (National Osteoporosis Foundation) reports that 1 in 2 women over 50 will experience an osteoporosis-related fracture in their lifetime [13].

HRT consistently reduces fracture risk. The WHI estrogen-plus-progestogen trial reported a 34 percent reduction in hip fracture risk (hazard ratio 0.66, 95% CI 0.45 to 0.98) [14]. Estrogen alone reduced hip fracture risk by 39 percent in the same program. That protection begins within the first year of use.

If HRT is not appropriate for you, discuss bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) or, for higher-risk patients, denosumab or romosozumab with your provider.

Cardiovascular and Metabolic Risks: Getting Your Numbers at Visit One

Menopause accelerates several cardiovascular risk factors. LDL cholesterol rises an average of 10 to 14 mg/dL in the perimenopause-to-postmenopause transition. Blood pressure and insulin resistance also increase [15]. That is why a fasting lipid panel and a fasting glucose or HbA1c at visit one give you a meaningful baseline.

The American Heart Association notes that women experience a disproportionate rise in cardiovascular disease risk after menopause compared to age-matched men, and that menopause itself is now recognized as a sex-specific cardiovascular risk factor [15]. Bring any prior lipid or glucose results to the visit so your provider can trend the values, not just read a single data point.